Drug Trial Reports Show Bias for Funder's Drug, UCSF Study Shows
University of California San Francisco
Displaying 13141 - 13170 of 16518
-
-
LAO Projects Huge Budget Deficits Through 2014
-
Panel Highlights Medical Promise of Stem Cells
-
Medical Community Looks to New Leadership for Health Care Reform
-
Breaking Ground: UCSF Builds Institute for Regeneration Medicine
-
In Young Men, HPV Vaccine Prevents Conditions That Lead to Cancer
-
UCSF to Become a Completely Smoke-Free Campus Today
-
UCSF Program Exposes Fourth-Graders to Opportunities in Higher Education
UCSF hosted nearly 100 fourth-graders from San Francisco’s E.R. Taylor Elementary School to learn about the connection between attending college and becoming a health care professional.
-
UCSF goes completely smoke free
UCSF will go completely smoke-free tomorrow, November 20, which is Great American Smoke-out Day.
-
UCSF Residents Receive Advocacy Awards
-
State Fiscal Crisis Further Depletes 2008-2009 UC Budget
-
UCSF Students Present Work to Thousands at National Public Health Conference
-
Flu Tracking Highlights Google Search Analysis as a Tool for Medicine
-
UCSF Launches 2008 Charitable Giving Campaign
-
Two cancer drugs prevent, reverse type 1 diabetes, UCSF study shows
Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco. The drugs – imatinib (marketed as Gleevec) and sunitinib (marketed as Sutent) – were found to put type 1 diabetes into remission in 80 percent of the test mice and work permanently in 80 percent of those that go into remission.
-
Fiscal Report from UCSF Senior Vice Chancellor Steve Barclay
-
UCSF Today Readers Comment on Election Results
-
AAMC Honors Schroeder as Anti-Smoking Crusader
-
UCTV to Webcast International Climate Summit
-
University Community Partnerships Program Requests Proposals for Grants
-
UCSF team moves in on mechanism in stem cell growth, possibly cancer
A class of miniscule molecules called microRNAs has become a major focus of biomedical research. Now, UCSF scientists have identified multiple members of this class that enable embryonic stem cells to divide, and thus proliferate, much more rapidly than the mature, or specialized, cells of the adult body.
-
Innovative center at UCSF specializes in treating the infant brain
UCSF Children’s Hospital has opened an innovative new clinical unit focusing on the infant brain that is the first facility of its kind in the United States. The unit brings together specialized treatment for infants who show signs of brain damage at birth – and are at-risk for developing cerebral palsy, mental retardation and other cognitive disorders – with clinical research.
-
UCSF Professor Offers Cure for Ailing Health Care System
-
UCSF cited as "most improved" UC medical school for diversity
The UCSF School of Medicine continues to have one of the most diverse student bodies among California medical schools, according to a public policy institute study. Nearly one-third of students in last fall’s entering class -- 28 percent -- are from groups underrepresented in medicine.
-
QB3, Gladstone Institutes Lauded For Role in Economic Development
-
UCSF Employee Arrested for Allegedly Poisoning Colleague
-
New Hope for HIV Treatment: Cells Exhausted from Fighting Infection can be Revitalized
-
UCSF Cardiologists Lead Nation in ER Heart Attack Care
-
New hope for HIV treatment: Cells exhausted from fighting HIV infection can be revitalized
Researchers at the University of Toronto and the University of California, San Francisco, have revealed new hope for HIV treatment with the discovery of a way to 'rescue' immune cells that are exhausted from fighting off HIV infection.
-
Study finds rise in rate of diagnostic imaging in managed care
Use of radiology imaging tests has soared in the past decade with a significant increase in newer technologies, according to a new study that is the first to track imaging patterns in a managed care setting over a substantial time period.